Syndax jumps after Q2 beat; Citi issues upside catalyst watch
I'm PortAI, I can summarize articles.
Syndax Pharmaceuticals (NASDAQ:SNDX) shares surged ~21% in premarket trading after reporting Q2 2025 financials that exceeded expectations, with ~$38.0M in revenue, surpassing forecasts by $11.3M. Strong sales from leukemia drug Revuforj ($28.6M) and graft-versus-host disease therapy Niktimvo ($36.2M) drove the results. Citi analyst Yigal Nochomovitz issued a 90-day upside catalyst watch, raising the price target from $46 to $51, citing potential for further stock gains as both treatments advance in the market.
Source: MSN The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments